Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
Authors:
Open Access
Abstract
Objective: To determine the relations of plasma levels of brain natriuretic peptide (BNP), atrial natriuretic factor (ANF), N-terminal ANF (N-ANF), cyclic guanosine monophosphate (cGMP; the cardiac peptide second messenger), and plasma catecholamines to left ventricular function and to prognosis in patients admitted with acute myocardial infarction. Design: Plasma hormones and ventricular function (radionuclide ventriculography) were measured 1–4 days after myocardial infarction in 220 patients admitted to a single coronary care unit. Radionuclide scanning was repeated 3–5 months after infarction. Clinical events were recorded over a mean period of 14 months. Results: Both early and late left ventricular ejection fraction (LVEF) were most closely related to plasma BNP (r = −0.60, n = 220, p < 0.001; andr = −0.53, n = 192, p < 0.001, respectively), followed by ANF, N-ANF, cGMP, and the plasma catecholamines. Early plasma BNP concentrations less than twofold the upper limit of normal (20 pmol/l) had 100% negative predictive value for LVEF < 40% at 3–5 months after infarction. In multivariate analysis incorporating all the neurohormonal factors, only BNP remained independently predictive of LVEF < 40% (p < 0.005). Survival analysis by median levels of candidate predictors identified BNP as the most powerful discriminator for death (p < 0.0001). No early deaths (within 4 months) occurred in patients with plasma BNP concentrations below the group median (27 pmol/l), and over follow up only three of 26 deaths occurred in this subgroup. Of all episodes of left ventricular failure, 85% occurred in patients with plasma BNP above the median (p < 0.001). In multivariate analyses, BNP alone gave additional predictive information beyond sex, age, clinical history, LVEF, and plasma noradrenaline for both subsequent onset of LVF and death. Conclusions: Plasma BNP measured within 1–4 days of acute myocardial infarction is a powerful independent predictor of left ventricular function, heart failure, or death over the subsequent 14 months, and superior to ANF, N-ANF, cGMP, and plasma catecholamines.Keywords
This publication has 30 references indexed in Scilit:
- Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular HypertrophyHypertension, 1996
- Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial InfarctionThe American Journal of Cardiology, 1996
- Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunctionThe American Journal of Cardiology, 1996
- Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failureThe American Journal of Cardiology, 1995
- Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarctionThe American Journal of Cardiology, 1993
- Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertensionThe American Journal of Cardiology, 1993
- Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarctionThe Lancet, 1993
- Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarctionHeart, 1992
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in manLife Sciences, 1981